Anticipating HIV Vaccines: Sketching an Agenda for Public Health Ethics and Policy in the United States
Year: 2015
Type: article
Abstract: PRÉCISWorldwide research and development expenditures on an HIV vaccine are approximately one billion U.S. dollars per year.While vaccines have been highly successful in preventing diseases, the most promising clinical trials to date suggest that a vaccine for HIV will be only moderately efficacious in preventing infection and will require multiple doses.We explore the ethical and policy implications of a moderately effective HIV vaccine.We examine anticipated costs, benefits, risks, and dissemination challenges.We conclude that a twofold approach of (1) using existing treatments to reduce viral loads and prevent transmission and (2) pursuing a cure for HIV may be more costeffective and beneficial in the long run than developing a vaccine.
Source: bepress Legal Repository
Authors: James M. DuBois, Amanda Hine, Michele Kennett, Kayla Kostelecky, Joseph M. Norris, Rachel M. Presti, Kathryn Raliski, Jessi Roach, Adam James Ruggles
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2996003294